Compare Abbott Laboratories (ABT) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Keysight Technologies Inc — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while Keysight Technologies Inc trades at $315.09 (market cap $52.83B). The key difference: Abbott Laboratories is far larger — about 3.2× Keysight Technologies Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| ABT | KEYS | |
|---|---|---|
Market Cap | $166.94B | $52.83B |
Sector | Health | Technology |
52-Week High | $136.62 | $373.34 |
52-Week Low | $82.57 | $158.51 |
Enterprise Value | $193.69B | $53.17B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Keysight Technologies (KEYS) trades at $309.12, down 1.51% today, with a bearish technical signal despite strong earnings beats in recent quarters. The company maintains solid profitability with a 63.67% gross margin and 17.31% net margin, though valuation multiples like a P/E of 51.49 appear elevated. Recent news highlights strategic collaborations in 6G and photonics, positioning KEYS for growth in AI and wireless markets.
The outlook is mixed: analyst consensus is bullish with a $390.30 price target (75% buy ratings), but technical weakness and high valuation pose near-term risks. Upside hinges on execution in high-frequency RF and photonics markets, while downside risks include competitive pressures and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
